{
    "nct_id": "NCT06580938",
    "official_title": "A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF PF-07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS",
    "inclusion_criteria": "1. Participants aged ≥18 years or older at the time of informed consent.\n2. Tumor types and prior treatment requirements: Participants entering Parts 2 and 3 must have at least 1 measurable lesion.\n\n   Part 1 and Part 2:\n\n   Eligible advanced/metastatic tumor types include NSCLC, urothelial carcinoma (UC), renal cell carcinoma (RCC), melanoma, head and neck squamous cell carcinoma (HNSCC), and microsatellite stable colorectal cancer (MSS-CRC). Participants must have demonstrated radiographic progression on standard treatment(s) for their cancer\n\n   Part 3:\n   * Cohort 1: Participants with metastatic melanoma with resistance to checkpoint inhibitor therapy and BRAF/MEKi.\n   * Cohort 2: Participants with metastatic MSS-CRC.\n   * Cohort 3: Participants with previously untreated metastatic NSCLC.\n3. ECOG PS 0 or 1.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Participants with any other active malignancy within 3 years prior to enrollment.\n2. Known or suspected hypersensitivity to, or severe allergic history of, human albumin or anti-PD-(L)1 therapy.\n3. History of Grade ≥3 immune-related AE (irAE) or unresolved irAEs prior to first dose of study intervention. Exception: vitiligo and endocrinopathy that is controlled with hormonal therapy.\n4. History of venous thromboembolic event <12 weeks prior to starting study treatment.\n5. Active or history of clinically significant gastrointestinal (GI) disease.\n6. Active or history of interstitial lung disease or Grade ≥2 pneumonitis.\n7. Active or history of clinically significant autoimmune disease.\n8. Active bleeding disorder.\n9. Participants who have undergone treatment with any investigational IL-12 agent.\n10. Active, uncontrolled infections",
    "miscellaneous_criteria": "Key"
}